FDA Approves Gazyva for Childhood Nephrotic Syndrome

Idiopathic nephrotic syndrome has never had an FDA-approved drug. Not one. Every regimen a pediatric nephrologist has reached for — corticosteroids since the disease was first managed with ACTH and cortisone decades ago, calcineurin inhibitors, the anti-CD20 antibody rituximab — has been prescribed off-label, borrowed from other diseases or built on institutional experience rather than a label FDA wrote for this condition. On 25 September 2026, that changed. FDA approved obinutuzumab (Gazyva, Genentech) to reduce relapse risk in patients 2 years and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome (INS) who are in complete remission.

A disease managed entirely off-label, until now

Idiopathic nephrotic syndrome is the most common form of nephrotic syndrome in children — a kidney disorder marked by heavy protein loss in the urine, low blood protein, and swelling, with a course that in many children relapses repeatedly through childhood. The frequently relapsing and steroid-dependent forms are the hardest to manage: children cycle through remission and relapse, often needing repeated steroid courses that carry their own long-term costs — growth suppression, bone density loss, cushingoid effects — or a step up to calcineurin inhibitors or rituximab, none of which carry an FDA-approved indication for this disease. Every one of those choices has been made, until this approval, entirely outside a label FDA had reviewed for INS specifically.

What INSHORE tested, and what it found

INSHORE was a randomized, controlled, open-label, multicenter Phase 3 trial in 85 patients ages 2 to 25 with childhood-onset, frequently relapsing or steroid-dependent INS, enrolled while in remission. It compared intravenous obinutuzumab, weight-based and dosed on Days 1 and 15 and again at Weeks 24 and 26, against twice-daily oral MMF — not a placebo, but the drug clinicians already reach for. The primary endpoint was sustained complete remission at week 52, defined as no relapse during the study and a urine protein-to-creatinine ratio of 0.2 or below at that 52-week mark. Obinutuzumab cleared it in 95.5% of patients against 73.2% on MMF, a statistically significant 23.39-percentage-point difference (95% CI 6.85–38.90; p=0.0031) that FDA accepted as the basis for approval.

The trade-off the label carries

Better remission came with a worse adverse-event profile. Overall adverse events ran higher on obinutuzumab than on MMF (95.5% vs. 82.9%), and grade 3-or-higher events were more than three times as common (25.0% vs. 7.3%). Obinutuzumab is an anti-CD20 monoclonal antibody delivered by infusion, and B-cell depletion carries its own familiar risk profile — infusion reactions and infection risk chief among them for a drug in this class. FDA weighed that against a disease whose current off-label standard of care itself carries real long-term costs, and approved the tighter remission control despite the higher event rate.

One drug, three kidney indications in under a year

This is Gazyva’s second immune-mediated kidney disease approval inside twelve months, following an October 2025 approval for adult lupus nephritis, and a third is already in the pipeline: FDA granted Priority Review in July 2026 for obinutuzumab in primary membranous nephropathy, a decision still pending. Genentech, a wholly owned member of the Roche Group, is building a life-cycle pattern here — one B-cell-depleting biologic, sequentially validated across a set of glomerular diseases that have historically been treated with the same generic, off-label toolkit regardless of the specific diagnosis underneath.

Frequently asked questions

What did FDA approve on 25 September 2026?

Obinutuzumab (Gazyva, Genentech) to reduce relapse risk in patients 2 years and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in complete remission — the first FDA-approved treatment option for the disease, according to Genentech.

What did the pivotal trial show?

INSHORE, a Phase 3 randomized trial in 85 patients ages 2–25, found sustained complete remission at week 52 in 95.5% of patients on obinutuzumab versus 73.2% on mycophenolate mofetil (adjusted difference 23.39 points, 95% CI 6.85–38.90, p=0.0031).

What is the safety trade-off?

Higher overall adverse events (95.5% vs. 82.9%) and grade ≥3 adverse events (25.0% vs. 7.3%) than with mycophenolate mofetil. FDA approved the drug on the remission data despite the higher event rate.

How is it dosed?

Intravenous infusion, weight-based, on Days 1 and 15 and again at Weeks 24 and 26 — the INSHORE trial schedule, per FDA's approval notice.